# US 6,727,240 B1 · Methods for preventing HIV-1 or HIV-2 infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,240 B1
- Document ID: US6727240B1
- Status: Granted
- Kind: B1
- Application number: 08/342,745
- Filed: 1994-10-21
- Granted: 2004-04-27
- Earliest claimed: 1993-12-28
- Assignees: New York Blood Center, Inc.
- Inventors: Alexander R. Neurath; Shibo Jiang; Asim Kumar Debnath
- Web page: https://patentgrep.com/patent/US6727240B1

## CPC

- A61K 31/695: Silicon compounds
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 31/765: Polymers containing oxygen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of preventing HIV-1 infection or HIV-2 infection comprising locally administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a protoporphyrin alone or in admixture with a pharmaceutically acceptable diluent, said protoporphyrin being tin protoporphyrin IX or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human is a female and tin protoporphyrin IX is vaginally administered.

### Claim 3 (depends on 2)

The method of claim 2, wherein tin protoporphyrin IX or a pharmaceutically acceptable salt thereof is administered prior to or during engaging in sexual intercourse.

### Claim 4 (depends on 2)

The method of claim 2, wherein tin protoporphyrin IX or a pharmaceutically acceptable salt thereof is administered in the form of a vaginal cream, lotion, ointment, gel, paste, jelly, spray, solution, emulsion or foam.

### Claim 5 (depends on 4)

The method of claim 4, wherein tin protoporphyrin IX or a pharmaceutically acceptable salt thereof is applied on a condom, a contraceptive diaphragm or a contraceptive sponge.

### Claim 6 (depends on 4)

The method of claim 4, wherein HIV-1 infection is prevented.

### Claim 7 (depends on 6)

The method of claim 6, wherein the HIV-1 is an isolate selected from the group consisting of IIIB, MN, RE, SF-2 and an isolate which replicates in the presence of AZT.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human is a human baby and tin protoporphyrin IX or a pharmaceutically acceptable salt thereof is topically administered to the baby after the birth of the baby.

### Claim 9 (depends on 1)

The method of claim 1, wherein the human body is a female and tin protoporphyrin IX or a pharmaceutically acceptable salt thereof is vaginally administered to the female during or before childbirth.

### Claim 10 (depends on 1)

The method of claim 1, wherein tin protoporphyrin IX is rectally administered.

### Claim 11

A method of preventing HIV-1 infection or HIV-2 infection comprising administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of tin mesoporphyrin IX or a pharmaceutically acceptable salt thereof alone or in admixture with a pharmaceutically acceptable diluent.

### Claim 12

A method of treating HIV-1 infection or HIV-2 infection comprising administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin mesoporphyrin or a pharmaceutically acceptable salt thereof, alone or in admixture with a pharmaceutically acceptable diluent.
